Skip to content

Section archive

Avastin

FDA is moving to withdraw Avastin's breast cancer indication after four studies showed it did not prolong survival or slow progression enough to outweigh risks including severe hypertension, bleeding, perforations and heart failure. Its other cancer approvals are unaffected.

1 min read

2 stories